Tech Company Financing Transactions
Locus Biosciences Funding Round
Locus Biosciences closed a $35 million Series B funding round on 5/18/2022. Backers included ARTIS Ventures, Johnson & Johnson Development Corporation and Tencent Holdings.
Transaction Overview
Company Name
Announced On
5/18/2022
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$35,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from this financing will support the advancement of lead candidate LBP-EC01, a crPhage precision medicine targeting Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs), into a registrational Phase 2/3 trial, and further development of the Company's preclinical programs focused on developing therapies for microbiome-associated diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
523 Davis Dr. 350
Morrisville, NC 27560
USA
Morrisville, NC 27560
USA
Phone
Website
Email Address
Overview
Locus Biosciences is an emerging biotechnology company focused on the discovery and development of a next generation CRISPR-Cas platform for precision antimicrobials. Our novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Garofolo
Chief Scientific Officer
David Ousterout
VP - Bus. Development
Paul Kim
VP - Bus. Development
Joseph Nixon
VP - Operations
Jamie Kime
Browse more venture capital transactions:
Prev: 5/18/2022: Masterschool venture capital transaction
Next: 5/18/2022: HowGood venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs